Epibiotech Co., Ltd. (XKON:446440)
South Korea
· Delayed Price · Currency is KRW
13,000
+1,000 (8.33%)
At close: Aug 8, 2025
Epibiotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2022 | FY 2021 |
| Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 449.62 | 387.85 |
| Other Revenue | 0 | - |
| Revenue | 449.62 | 387.85 |
| Revenue Growth (YoY) | 15.93% | - |
| Cost of Revenue | 177.38 | 163.21 |
| Gross Profit | 272.25 | 224.64 |
| Selling, General & Admin | 1,527 | 1,292 |
| Research & Development | 2,976 | 1,755 |
| Other Operating Expenses | 63.67 | 45.69 |
| Operating Expenses | 5,311 | 3,466 |
| Operating Income | -5,038 | -3,242 |
| Interest Expense | -91.47 | -73.66 |
| Interest & Investment Income | 64.42 | 51.29 |
| Currency Exchange Gain (Loss) | 53.22 | 67.72 |
| Other Non Operating Income (Expenses) | -7.36 | 1.03 |
| EBT Excluding Unusual Items | -5,020 | -3,195 |
| Gain (Loss) on Sale of Assets | -38.21 | - |
| Pretax Income | -5,058 | -3,195 |
| Net Income | -5,058 | -3,195 |
| Net Income to Common | -5,058 | -3,195 |
| Shares Outstanding (Basic) | 2 | 2 |
| Shares Outstanding (Diluted) | 2 | 2 |
| Shares Change (YoY) | 0.60% | - |
| EPS (Basic) | -2966.00 | -1885.00 |
| EPS (Diluted) | -2966.00 | -1885.00 |
| Free Cash Flow | -5,124 | -4,569 |
| Free Cash Flow Per Share | -3004.95 | -2695.24 |
| Gross Margin | 60.55% | 57.92% |
| Operating Margin | -1120.59% | -835.82% |
| Profit Margin | -1124.91% | -823.86% |
| Free Cash Flow Margin | -1139.68% | -1177.98% |
| EBITDA | -4,294 | -2,868 |
| D&A For EBITDA | 743.99 | 373.93 |
| EBIT | -5,038 | -3,242 |
| Advertising Expenses | 42.45 | 30.53 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.